134 related articles for article (PubMed ID: 37649416)
1. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
[TBL] [Abstract][Full Text] [Related]
2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
3. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
4. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.
Kam YN; McKenzie K; Coyle M; Bertin FR
J Vet Intern Med; 2021 Nov; 35(6):2885-2890. PubMed ID: 34642962
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
Vet J; 2023; 300-302():106035. PubMed ID: 37802466
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
Horn R; Bertin FR
J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
[TBL] [Abstract][Full Text] [Related]
7. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.
Horn R; Stewart AJ; Jackson KV; Dryburgh EL; Medina-Torres CE; Bertin FR
J Vet Intern Med; 2021 Jan; 35(1):560-570. PubMed ID: 33368633
[TBL] [Abstract][Full Text] [Related]
9. Effect of early or late blood sampling on thyrotropin releasing hormone stimulation test results in horses.
Thane K; Uricchio C; Frank N
J Vet Intern Med; 2022 Mar; 36(2):770-777. PubMed ID: 35049089
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dynamic testing for pituitary pars intermedia dysfunction diagnosis in donkeys.
Mejia-Pereira S; Perez-Ecija A; Buchanan BR; Toribio RE; Mendoza FJ
Equine Vet J; 2019 Jul; 51(4):481-488. PubMed ID: 30362589
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of equine pituitary pars intermedia dysfunction.
Stewart AJ; Ireland JL; Durham AE; McGowan CM
Vet J; 2023; 300-302():106036. PubMed ID: 37805159
[TBL] [Abstract][Full Text] [Related]
13. Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia.
Byrne DP; Secombe CJ; Tan RHH; Perera DI; Watts SP; Wearn JG
Vet J; 2018 Aug; 238():58-62. PubMed ID: 30103916
[TBL] [Abstract][Full Text] [Related]
14. Influence of feeding and other factors on adrenocorticotropin concentration and thyrotropin-releasing hormone stimulation test in horses and ponies.
Drozdzewska K; Winter J; Barton AK; Merle R; Gehlen H
Equine Vet J; 2024 Mar; 56(2):342-351. PubMed ID: 38010866
[TBL] [Abstract][Full Text] [Related]
15. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
Miller AB; Murphy BA; Adams AA
Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
[TBL] [Abstract][Full Text] [Related]
16. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
[TBL] [Abstract][Full Text] [Related]
17. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
McFarlane D; Beech J; Cribb A
Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
[TBL] [Abstract][Full Text] [Related]
18. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
20. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
Durham AE
Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
